Article Text
Abstract
This article lays out a wide spectrum of candidate ethical solutions for the challenge on which this JME symposium focuses: the benefit:risk ratio challenge to some early-phase HIV cure and remission studies. These candidate solutions fall into four categories: ones that seek to reduce risks in early-phase HIV cure and remission studies, ones that enhance the benefits for these studies’ participants (or show that those were adequate in the first place), ones that focus on participants’ free and informed consent to participate and ones according to whom the large benefits to non-participants can defeat considerations about individual participant net risks. In so doing, this article also structures the rest of the symposium.
- HIV Infection and AIDS
- Research Ethics
- Ethics
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Footnotes
Funding This work was funded by NIAID grants 1 R01 AI114617-01A1 and 1 R56 AI114617-01, both titled ‘HIV cure studies: risk, risk perception and ethics’.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Benefits to nonparticipants
Other content recommended for you
- The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
- When to start paediatric testing of the adult HIV cure research agenda?
- Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors
- Informed consent to HIV cure research
- Why cure, why now?
- Individual risk and community benefit in international research
- First-in-human HIV-remission studies: reducing and justifying risk
- Assessing research risks systematically: the net risks test
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
- Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae and Martin Delaney